Renaissance Technologies LLC Has $5.15 Million Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

Renaissance Technologies LLC boosted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 14.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 73,400 shares of the company’s stock after purchasing an additional 9,300 shares during the quarter. Renaissance Technologies LLC owned about 0.17% of Tarsus Pharmaceuticals worth $5,149,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in TARS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Tarsus Pharmaceuticals by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock worth $1,137,000 after buying an additional 1,217 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Tarsus Pharmaceuticals by 2.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock worth $3,659,000 after buying an additional 1,394 shares during the last quarter. Jane Street Group LLC lifted its holdings in Tarsus Pharmaceuticals by 105.8% in the first quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after buying an additional 190,000 shares during the period. JPMorgan Chase & Co. boosted its stake in Tarsus Pharmaceuticals by 402.7% in the second quarter. JPMorgan Chase & Co. now owns 140,610 shares of the company’s stock valued at $5,696,000 after acquiring an additional 112,637 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Tarsus Pharmaceuticals by 12.3% in the second quarter. Invesco Ltd. now owns 928,501 shares of the company’s stock valued at $37,614,000 after acquiring an additional 101,978 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on TARS. HC Wainwright reiterated a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Guggenheim dropped their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, July 21st. Finally, Oppenheimer began coverage on Tarsus Pharmaceuticals in a research note on Friday, April 24th. They issued an “outperform” rating and a $98.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $90.17.

Insiders Place Their Bets

In other news, Director Katherine Goodrich sold 2,954 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $62.08, for a total transaction of $183,384.32. Following the sale, the director owned 2,233 shares of the company’s stock, valued at $138,624.64. This trade represents a 56.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $61.55, for a total value of $615,500.00. Following the sale, the chief executive officer directly owned 847,991 shares in the company, valued at approximately $52,193,846.05. This represents a 1.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 39,850 shares of company stock worth $2,452,821. 9.64% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals Stock Up 6.6%

Shares of NASDAQ TARS opened at $65.33 on Friday. Tarsus Pharmaceuticals, Inc. has a 52-week low of $44.67 and a 52-week high of $85.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. The stock has a market cap of $2.81 billion, a P/E ratio of -57.31 and a beta of 0.53. The firm has a 50 day moving average price of $61.29 and a 200 day moving average price of $64.94.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The firm had revenue of $173.91 million during the quarter, compared to analyst estimates of $169.68 million. Analysts expect that Tarsus Pharmaceuticals, Inc. will post -1.27 EPS for the current year.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Strategic acquisition expands the pipeline: Tarsus agreed to acquire Alkeus Pharmaceuticals for $450 million upfront, with potential total consideration of up to $800 million. The deal adds gildeuretinol (ALK-001), a Phase 3 oral treatment candidate for Stargardt disease, a sizable inherited retinal disorder with no FDA-approved therapy. The asset provides a potential blockbuster opportunity and strengthens Tarsus’ position in eye care. Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
• Positive Sentiment: Commercial momentum remained strong: Second-quarter XDEMVY net product sales reached $173.9 million, up more than 69% year over year and ahead of the approximately $169.7 million analyst consensus. Continued growth of the FDA-approved Demodex blepharitis treatment supports Tarsus’ ability to fund expansion and invest in its pipeline. Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
• Neutral Sentiment: Institutional support is mixed: Recent filings showed 112 institutions adding TARS shares while 117 reduced positions. Analysts cited in the reports maintained price targets between $88 and $105, above the recent trading level, but these targets may not fully reflect the acquisition’s execution risks.
• Negative Sentiment: Quarterly loss exceeded expectations: Tarsus reported a loss of $0.43 per share, worse than the roughly $0.19–$0.21 consensus loss, despite the revenue beat. The company remains unprofitable, which could increase sensitivity to acquisition costs and future research spending. Tarsus Pharmaceuticals Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Funding creates dilution: Tarsus announced an oversubscribed $125 million private placement to help support the Alkeus transaction and growth initiatives. While the financing improves liquidity, issuing new shares dilutes existing holders. Investors may also be concerned that insiders reported selling shares, with no purchases, during the past six months. Tarsus Pharmaceuticals Announces $125 Million Private Placement

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro?effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early?stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.